Infigratinib, a selective FGFR1-3 tyrosine kinase inhibitor, alters dentoalveolar development at high doses.

Zachary D Michel, Sarah F Aitken,Omar D Glover, Lucy O Alejandro, Davide Randazzo,Carl Dambkowski,David Martin,Michael T Collins,Martha J Somerman,Emily Y Chu

Developmental dynamics : an official publication of the American Association of Anatomists（2023）

引用 0|浏览0

暂无评分

摘要

High dose infigratinib administered to rats during early stages affects dental and craniofacial development. Changes in CTSK from infigratinib in female rats suggest FGFR roles in bone homeostasis. While dental and craniofacial disruptions are not expected at therapeutic doses, our findings confirm the importance of dental monitoring in clinical studies.

查看译文

关键词

dentoalveolar development,tyrosine kinase,inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要